The purpose of this study is to conduct a comparative analysis of patients using Tiotropium in combination with Inhaled Corticosteroids (ICS) versus those that use long-acting β2-agonists (LABA) medication in combination with ICS.
Study Type
OBSERVATIONAL
Enrollment
1,899
eMax Health
White Plains, New York, United States
Time to First Severe Exacerbation
Severe exacerbation defined as: * Hospitalization with primary diagnosis of asthma or * Emergency room (ER) visit with primary diagnosis of asthma The analysis of this endpoint is based on number of observations (exacerbations). Index date is defined as date when patient entered the cohort. Design 1: A time-varying covariate approach to classify drug exposure time for each comparator drug during follow up was used. For each individual study drug, medication exposure + non-exposure windows during the follow-up time for each medication were identified/defined using date of prescription filled + days' supply listed on prescription claim + 50% additional days.
Time frame: From index date to first severe exacerbation, up to 1 year.
Time to First Moderate-or-severe Exacerbation
Severe exacerbation defined as: * Hospitalization with primary diagnosis of asthma or * Emergency room (ER) visit with primary diagnosis of asthma The analysis of this endpoint is based on number of observations (exacerbations). Index date is defined as date when patient entered the cohort. Design 1: A time-varying covariate approach to classify drug exposure time for each comparator drug during follow up was used. For each individual study drug, medication exposure + non-exposure windows during the follow-up time for each medication were identified/defined using date of prescription filled + days' supply listed on prescription claim + 50% additional days.
Time frame: From index date to first moderate-or-severe exacerbation, up to 1 year.
Percentage of Patients With Exacerbation
Percentage of patients with exacerbation is presented. Design 2: The second analysis, included on an ad-hoc basis was using an intent-to-treat (ITT) design where patients were assigned to the cohort, they were part of at the index date.
Time frame: From index date through first report of exacerbation, up to 1 year.
Rate of Exacerbation at 6 Months and One Year
Rate of exacerbation at 6 months and one year is presented.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: at 6 months and one year
Percentage of Patients With Health Care Resource Utilization (HCRU)
Percentage of patients with Health care resource utilization (HCRU) is presented and is defined as hospitalizations, emergency room (ER) visits, and outpatient visits during follow-up, all-cause and asthma related.
Time frame: From index date to end of follow-up, up to 1 year.
Health Care Resource Utilization (HCRU)
Health care resource utilization (HCRU) are presented including frequency of hospitalizations, ER visits, outpatient visits. Outpatient visits are defined as clinic, hospital, or other medical institution (e.g. public health, etc.) visit as an outpatient. Mean and standard deviations of: * Number of hospitalisations per person per month * Number of asthma-related hospitalisations per person per month * Number of ER visits per person per month * Number of asthma-related ER visits per person per month * Number of outpatient visits per person per month * Number of asthma-related outpatient visits per person per month are presented.
Time frame: From index date to end of follow-up, up to 1 year.
Percentage of Patients With Use of Rescue Medications
Percentage of patients with use of rescue medications is presented. Use of rescue medication is defined as patients with one or more short-acting β2-agonists (SABA) claims during the follow-up period.
Time frame: From index date to end of follow-up, up to 1 year.